Core Viewpoint - Nutex Health Inc. is facing legal scrutiny due to a class-action lawsuit alleging deceptive billing practices that artificially inflated its financial results [1][2][9] Legal Allegations - The lawsuit claims Nutex collaborated with HaloMD to submit ineligible insurance claims, misleading shareholders and causing significant financial losses [1][2] - Allegations include a systematic effort to exploit the insurance arbitration process, submitting thousands of questionable claims to extract excessive reimbursements [2][3] Market Reaction - Following the release of a report by activist short-seller Blue Orca Capital, Nutex's stock dropped over 10%, reflecting investor concerns about the company's reliance on arbitration reimbursements [3][4] Financial Misrepresentation - The lawsuit asserts that Nutex misrepresented its progress in addressing internal control deficiencies, particularly in misclassifying stock-based compensation obligations [5] - Nutex's shares fell 16.39% after the company announced a delay in its Form 10-Q filing due to "non-cash accounting adjustments" [6] Audit Findings - On August 21, Nutex disclosed that its Audit Committee determined certain prior financial statements required restatement due to incorrect classification of obligations related to hospital development [7] Investor Impact - The class-action suit seeks to recover damages for investors who acquired Nutex securities during the alleged misrepresentation period, arguing that public disclosures were materially misleading [9] Ongoing Investigations - Law firm Hagens Berman is investigating the claims against Nutex, focusing on whether the company's business model relied on questionable arbitration tactics and misleading financial reporting practices [10]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Nutex Health Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on October 21, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Nutex securities between August 8, 2024, and August 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. Group 2: Allegations Against Nutex - The lawsuit alleges that Nutex made false and misleading statements regarding its financial practices, including the involvement of HaloMD in fraudulent activities to achieve favorable arbitration results [4]. - It is claimed that Nutex overstated its ability to remediate weaknesses in its internal controls over financial reporting, leading to improper accounting of stock-based compensation obligations [4]. - The allegations suggest that these misrepresentations inflated Nutex's business and financial prospects, resulting in investor damages when the truth was revealed [4].

Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nutex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nutex between August 8, 2024 and August 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212- 983-9330Â (Ext. 1310). Faruqi & Faruqi is a leading national securities law firm with office ...

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for allegedly making materially false and misleading statements regarding its business operations and financial prospects during the Class Period from August 8, 2024, to August 14, 2025 [3][8]. Allegation Details - The lawsuit claims that Nutex engaged in a scheme to defraud insurance companies through HaloMD, leading to unsustainable revenue [3]. - It is alleged that Nutex overstated its ability to remediate material weaknesses in its internal controls over financial reporting [3]. - The company reportedly misclassified stock-based compensation obligations, increasing the risk of failing to file timely financial reports with the SEC [3]. - Overall, the public statements made by Nutex were deemed materially false and misleading throughout the relevant period [3]. Next Steps - Investors who purchased Nutex shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][8]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 21, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Nutex Health Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on October 21, 2025, for a class action lawsuit [1][2] Group 1: Class Action Details - Investors who bought Nutex securities between August 8, 2024, and August 14, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] Group 2: Case Allegations - The lawsuit alleges that Nutex made false and misleading statements regarding its financial practices and internal controls, particularly concerning its relationship with HaloMD, a third-party vendor [4] - Specific claims include that Nutex's revenues from HaloMD were unsustainable due to fraudulent conduct, and that the company overstated its ability to remediate weaknesses in its financial reporting [4] - The allegations suggest that Nutex improperly classified stock-based compensation obligations, which increased the risk of failing to file timely financial reports with the SEC [4]

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for allegedly making materially false and misleading statements regarding its business operations and financial prospects during the Class Period from August 8, 2024, to August 14, 2025 [3][8]. Allegation Details - The lawsuit claims that Nutex engaged in a scheme to defraud insurance companies through HaloMD, leading to unsustainable revenue [3]. - It is alleged that Nutex overstated its ability to remediate weaknesses in its internal controls over financial reporting, affecting the accounting treatment of stock-based compensation obligations [3]. - The company reportedly misclassified stock-based compensation obligations as equity instead of liabilities, increasing the risk of failing to file timely financial reports with the SEC [3]. - Overall, the lawsuit asserts that Nutex's public statements were materially false and misleading throughout the relevant period [3]. Next Steps - Investors who purchased Nutex shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][8]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 21, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Points - Nutex Health, Inc. is facing a class action lawsuit for investors who purchased securities between August 8, 2024, and August 14, 2025, with a deadline to file a lead plaintiff motion by October 21, 2025 [1] - Blue Orca Capital issued a short report on July 22, 2025, alleging that Nutex is exposed to litigation risk due to its association with HaloMD, which is involved in a fraudulent scheme against insurance companies [3] - Following the release of the Blue Orca report, Nutex's stock price dropped by $11.18 per share, or 10.05%, closing at $100.01 per share on the same day [3] Legal Representation - The Portnoy Law Firm is representing investors in claims related to corporate misconduct and offers complimentary case evaluations [2][4] - The founding partner of the Portnoy Law Firm has successfully recovered over $5.5 billion for investors in the past [4]

Core Viewpoint - Nutex Health Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 8, 2024, and August 14, 2025, impacting investors adversely [1][2]. Group 1: Allegations and Company Impact - The lawsuit claims that Nutex Health Inc. made false statements regarding its third-party vendor HaloMD, which allegedly engaged in fraudulent activities to achieve favorable arbitration results [1]. - It is alleged that revenues from Nutex's engagement with HaloMD were unsustainable due to the fraudulent nature of the conduct [1]. - The company purportedly overstated its ability to remediate material weaknesses in its internal controls over financial reporting, leading to improper accounting of stock-based compensation obligations [1]. - As a result of these issues, Nutex Health Inc. may have overstated its business and financial prospects, making public statements materially false and misleading [1]. Group 2: Legal Proceedings and Participation - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [2]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [2].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Nutex Health Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on October 21, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Nutex securities between August 8, 2024, and August 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2][6]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Nutex made false and misleading statements regarding its financial practices, including the engagement with HaloMD, which allegedly defrauded insurance companies [4]. - It is claimed that Nutex overstated its financial health and internal controls, leading to improper accounting of stock-based compensation obligations [4]. - The lawsuit asserts that these misrepresentations resulted in damages to investors when the true details became public [4].

Core Viewpoint - Nutex Health Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 8, 2024, and August 14, 2025, impacting investors adversely [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Nutex Health Inc. made false statements regarding its third-party vendor HaloMD, which allegedly engaged in fraudulent activities to defraud insurance companies [2]. - It is alleged that revenues from Nutex's engagement with HaloMD were unsustainable due to the fraudulent nature of the conduct [2]. - The company is accused of overstating its remediation efforts regarding material weaknesses in its internal controls over financial reporting [2]. - Nutex reportedly failed to accurately account for stock-based compensation obligations, misclassifying them as equity instead of liabilities [2]. - These issues increased the risk of Nutex being unable to file financial reports with the SEC in a timely manner, leading to an overstatement of the company's business and financial prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].